Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats

Brain Research

Volumn 953, Issue 1-2, 2002, Pages 112-118

  Busch, Elmar ^a   Beaulieu, Christian ^b   De Crespigny, Alex ^c   Kreischer, Sonja ^a   Diener, Hans Christoph ^a   Moseley, Michael E ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Diffusion MRI; Perfusion MRI; Rat; rt PA; Stroke; Thrombolytic therapy

Indexed keywords

ALTEPLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN SURGERY; CONTROLLED STUDY; DIFFUSION; DRUG EFFECT; HEMISPHERE; MIDDLE CEREBRAL ARTERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; RECANALIZATION; REPERFUSION; STROKE; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR ACCIDENT; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FIBRINOLYTIC AGENTS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037145702     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03276-6     Document Type: Article

References (20)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group . Tissue plasminogen activator for acute ischemic stroke. New Engl. J. Med. 333:1995;1581-1587. http://content.nejm.org/cgi/content/full/333/24/1581.
2. Back T., Hoehn-Berlage M., Kohno K., Hossmann K.A. Diffusion nuclear magnetic resonance imaging in experimental stroke. Correlation with cerebral metabolites. Stroke. 25:1994;494-500.
3. Beaulieu C., Busch E., Rother J., de Crespigny A., Hsia C.J., Moseley M.E. Polynitroxyl albumin reduces infarct size in transient focal cerebral ischemia in the rat: potential mechanisms studied by magnetic resonance imaging. J. Cereb. Blood. Flow. Metab. 18:1998;1022-1031.
4. Busch E., Kruger K., Allegrini P.R., Kerskens C.M., Gyngell M.L., Hoehn-Berlage M., Hossmann K.A. Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance and biochemical imaging. J. Cereb. Blood Flow. Metab. 18:1998;407-418.
5. Busch E., Kruger K., Fritze K., Allegrini P.R., Hoehn-Berlage M., Hossmann K.A. Blood-brain barrier disturbances after rt-PA treatment of thromboembolic stroke in the rat. Acta Neurochir. Suppl. (Wien). 70:1997;206-208.
6. Busch E., Kruger K., Hossmann K.A. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res. 778:1997;16-24.
7. Conforti G., Dominguez-Jimenez C., Ronne E., Hoyer-Hansen G., Dejana E. Cell-surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer. Blood. 83:1994;994-1005.
8. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., Boysen G., Bluhmki E., Hoxter G., Mahagne M.H., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J. Am. Med. Assoc. 274:1995;1017-1025.
9. Kilic E., Hermann D.M., Hossmann K.A. Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport. 10:1999;107-111. http://www.neuroreport.com/article.asp?ISSN=09594965&VOL= 10&ISS=1&PAGE=10.
10. Klein G.M., Li H., Sun P., Buchan A.M. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology. 52:1999;1381-1384.
11. Korninger C., Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 46:1981;561-565.
12. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E.T., Vivien D., Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7:2001;59-64.
13. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow. Metab. 10:1990;290-293.
14. Tabrizi P., Wang L., Seeds N., McComb J.G., Yamada S., Griffin J.H., Carmeliet P., Weiss M.H., Zlokovic B.V. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler. Thromb. Vasc. Biol. 19:1999;2801-2806. http://atvb.ahajournals.org/cgi/content/full/19/11/2801.
15. Traynelis S.F., Lipton S.A. Is tissue plasminogen activator a threat to neurons? Nat. Med. 7:2001;17-18.
16. Tsirka S.E. Clinical implications of the involvement of tPA in neuronal cell death. J. Mol. Med. 75:1997;341-347. http://link.springerny.com/link/service/journals/00109/bibs/7075005/ 70750341.htm.
17. Tsirka S.E., Gualandris A., Amaral D.G., Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature. 377:1995;340-344.
18. Tsirka S.E., Rogove A.D., Strickland S. Neuronal cell death and tPA. Nature. 384:1996;123-124.
19. Vivien D., Buisson A. Serine protease inhibitors: novel therapeutic targets for stroke? J. Cereb. Blood Flow. Metab. 20:2000;755-764.
20. Wang Y.F., Tsirka S.E., Strickland S., Stieg P.E., Soriano S.G., Lipton S.A. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4:1998;228-231.